# Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )

> **NCT00236002** · PHASE3 · TERMINATED · sponsor: **Canadian Urology Research Consortium** · enrollment: 182 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Alendronate

## Key facts

- **NCT ID:** NCT00236002
- **Lead sponsor:** Canadian Urology Research Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2007-11
- **Final completion:** 2009-08
- **Target enrollment:** 182 (ACTUAL)
- **Why stopped:** Slow accrual than anticipated.
- **Last updated:** 2009-08-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00236002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00236002, "Cancer and Osteoporosis Research With Alendronate and Lupron (C.O.R.A.L )". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00236002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*